Literature DB >> 15307819

Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator.

Alfredo Martínez1, Hae-Ryong Oh, Edward J Unsworth, Claudia Bregonzio, Juan M Saavedra, William G Stetler-Stevenson, Frank Cuttitta.   

Abstract

MMPs (matrix metalloproteinases) play a major role in the pathogenesis of hypertension by altering the extracellular matrix during cardiovascular remodelling. In the present study we show that MMP-2, but not MMP-9, cleaves the vasodilator peptide AM (adrenomedullin). Addition of the AM-binding protein, complement factor H, prevents this cleavage, providing a hitherto unknown mechanism of action for this binding protein. We identified the signature cleavage fragments and found some of them in human urine, suggesting that MMP-2 processing of AM may occur in vivo. Synthetic AM fragments regulated blood pressure in rats. The larger peptides are vasodilators, as is intact AM, whereas intermediate fragments did not affect blood pressure. In contrast, AM(11-22) elicited vasoconstriction. Studies of AM receptor activation in Rat2 cells confirm that the larger AM cleavage peptides activated this receptor, whereas AM(11-22) did not. The present study defines a new mechanism through which MMP-2 may regulate blood pressure by simultaneously eliminating a vasodilator and generating a vasoconstrictor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15307819      PMCID: PMC1133733          DOI: 10.1042/BJ20040920

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  33 in total

1.  Characterization of matrix metalloproteinases in human urine: alterations during adolescence.

Authors:  K M Thrailkill; S Kumar; C K Rosenberg; K J Auten; J L Fowlkes
Journal:  Pediatr Nephrol       Date:  1999-04       Impact factor: 3.714

2.  Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction.

Authors:  C Fernandez-Patron; K G Stewart; Y Zhang; E Koivunen; M W Radomski; S T Davidge
Journal:  Circ Res       Date:  2000-10-13       Impact factor: 17.367

3.  RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor.

Authors:  L M McLatchie; N J Fraser; M J Main; A Wise; J Brown; N Thompson; R Solari; M G Lee; S M Foord
Journal:  Nature       Date:  1998-05-28       Impact factor: 49.962

4.  Degradation of human adrenomedullin(1-52) by plasma membrane enzymes and identification of metabolites.

Authors:  L K Lewis; M W Smith; S O Brennan; T G Yandle; A M Richards; M G Nicholls
Journal:  Peptides       Date:  1997       Impact factor: 3.750

5.  Rat-2 fibroblasts express specific adrenomedullin receptors, but not calcitonin-gene-related-peptide receptors, which mediate increased intracellular cAMP and inhibit mitogen-activated protein kinase activity.

Authors:  H A Coppock; A A Owji; C Austin; P D Upton; M L Jackson; J V Gardiner; M A Ghatei; S R Bloom; D M Smith
Journal:  Biochem J       Date:  1999-02-15       Impact factor: 3.857

6.  Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats.

Authors:  H D Intengan; E L Schiffrin
Journal:  Hypertension       Date:  2000-06       Impact factor: 10.190

7.  Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor.

Authors:  C Fernandez-Patron; M W Radomski; S T Davidge
Journal:  Circ Res       Date:  1999-11-12       Impact factor: 17.367

8.  Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3.

Authors:  G A McQuibban; J H Gong; E M Tam; C A McCulloch; I Clark-Lewis; C M Overall
Journal:  Science       Date:  2000-08-18       Impact factor: 47.728

9.  Adrenomedullin (16-31) has pressor activity in the rat but not the cat.

Authors:  H C Champion; D E Friedman; D G Lambert; W A Murphy; D H Coy; P J Kadowitz
Journal:  Peptides       Date:  1997       Impact factor: 3.750

10.  Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin.

Authors:  O Lisy; M Jougasaki; J A Schirger; H H Chen; P T Barclay; J C Burnett
Journal:  Am J Physiol       Date:  1998-09
View more
  39 in total

1.  Attenuation of renal ischemia and reperfusion injury by human adrenomedullin and its binding protein.

Authors:  Kavin G Shah; Derry Rajan; Asha Jacob; Rongqian Wu; Kambhampaty Krishnasastry; Jeffrey Nicastro; Ernesto P Molmenti; Gene F Coppa; Ping Wang
Journal:  J Surg Res       Date:  2010-04-24       Impact factor: 2.192

2.  Matrix metalloproteinases activities in hypertension: emerging opportunities.

Authors:  Geert W Schmid-Schönbein
Journal:  Hypertension       Date:  2010-11-15       Impact factor: 10.190

3.  Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension.

Authors:  C S Ceron; M M Castro; E Rizzi; M F Montenegro; V Fontana; M C O Salgado; R F Gerlach; J E Tanus-Santos
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

4.  Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth.

Authors:  Rebecca A Mosig; Oonagh Dowling; Analisa DiFeo; Maria Celeste M Ramirez; Ian C Parker; Etsuko Abe; Janane Diouri; Aida Al Aqeel; James D Wylie; Samantha A Oblander; Joseph Madri; Paolo Bianco; Suneel S Apte; Mone Zaidi; Stephen B Doty; Robert J Majeska; Mitchell B Schaffler; John A Martignetti
Journal:  Hum Mol Genet       Date:  2007-03-30       Impact factor: 6.150

5.  Intracellular proadrenomedullin-derived peptides decorate the microtubules and contribute to cytoskeleton function.

Authors:  Dan L Sackett; Laurent Ozbun; Enrique Zudaire; Lisa Wessner; John M Chirgwin; Frank Cuttitta; Alfredo Martínez
Journal:  Endocrinology       Date:  2008-03-06       Impact factor: 4.736

6.  Resuscitation of uncontrolled traumatic hemorrhage induced by severe liver injury: the use of human adrenomedullin and adrenomedullin binding protein-1.

Authors:  Kavin G Shah; Asha Jacob; Derry Rajan; Rongqian Wu; Ernesto P Molmenti; Jeffrey Nicastro; Gene F Coppa; Ping Wang
Journal:  J Trauma       Date:  2010-12

7.  Pro-inflammatory cytokines from Kupffer cells downregulate hepatocyte expression of adrenomedullin binding protein-1.

Authors:  Asha Jacob; Mian Zhou; Rongqian Wu; Vivienne J Halpern; Thanjavur S Ravikumar; Ping Wang
Journal:  Biochim Biophys Acta       Date:  2007-04-06

8.  Inhibition of the adrenomedullin/nitric oxide signaling pathway in early diabetic retinopathy.

Authors:  Jan J Blom; Thomas J Giove; Tara L Favazza; James D Akula; William D Eldred
Journal:  J Ocul Biol Dis Infor       Date:  2012-01-12

Review 9.  Matrix metalloproteinases as drug targets in preeclampsia.

Authors:  Ana C T Palei; Joey P Granger; Jose E Tanus-Santos
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

10.  B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity.

Authors:  Guido Boerrigter; Lisa C Costello-Boerrigter; Gail J Harty; Brenda K Huntley; Alessandro Cataliotti; Harald Lapp; John C Burnett
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-04-22       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.